Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products.

J E Megías-Vericat, S Bonanad Boix,R Berrueco Moreno, M E Mingot-Castellano,M Rodríguez López,M Canaro Hirnyk,J Mateo Arranz, J M Calvo Villas, S Haya Guaita, M Mesegué Medà, F López Jaime, C Albo-López, A Palomero-Massanet, N Vilalta Seto,I Larrodé Leciñena, A R Cid Haro, J L Poveda Andrés

Thrombosis research（2022）

引用 5|浏览12

暂无评分

摘要

•Extended half-life (EHL) factors increased bleeding protection in clinical trials.•Pharmacokinetics & clinical variables were compared in 2 periods after EHL switch.•EHL achieved improvements in pharmacokinetics, bleeding rates & treatment burden.•Benefits were reported with different EHL products and in all the age subgroups.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要